Estados Unidos · Plataformas y datos · Morningstar

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Publicado por Morningstar · Estados Unidos hace 10 h

Supports serial testing in the surveillance setting for patients with early-stage HCC Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

También te puede interesar

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Treasury yields edge up as Election Day meets JOLTS, refunding

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Compartir

También te puede interesar

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Treasury yields edge up as Election Day meets JOLTS, refunding